---
title: "Unicycive net loss widens 147% to USD 14.55 million in FY26 first half"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295650032.md"
description: "Unicycive Therapeutics reported a GAAP net loss of USD 14.55 million for the first half of FY26, a 147% widening. Operating losses increased 46% to USD 10.14 million due to higher R&D and administrative costs. Additionally, the FDA issued a complete response letter on June 30, 2026, citing manufacturing deficiencies in the resubmitted OLC NDA."
datetime: "2026-08-12T10:32:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295650032.md)
  - [en](https://longbridge.com/en/news/295650032.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295650032.md)
---

# Unicycive net loss widens 147% to USD 14.55 million in FY26 first half

-   Unicycive posted a GAAP net loss of USD 14.55 million for the six months ended June 30, 2026, widening 147%. \* Quarterly GAAP net loss narrowed to USD 1.72 million, swinging from USD 6.45 million a year earlier on higher other income. \* Operating loss widened 46% to USD 10.14 million, as R&D expense rose 59% to USD 2.79 million. \* General and administrative costs climbed 41% to USD 7.35 million, including a USD 0.4 million increase tied to commercial launch preparation. \* FDA issued a complete response letter for the resubmitted OLC NDA on June 30, 2026, citing the same third-party manufacturing deficiencies as 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088013), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [GE HealthCare declares Q3 2026 distribution of R$ 0.02 per unit](https://longbridge.com/en/news/296242723.md)
- [Diageo announces BRL 0.32 per unit distribution for Q3 2026](https://longbridge.com/en/news/295964479.md)
- [Wallix updates financial calendar, sets release of 2026 half-year results](https://longbridge.com/en/news/296258764.md)